Publications by authors named "Shunlong Ou"
To date, the definition that the off-label usage of drugs refers to the unapproved use of approved drugs, which covers unapproved indications, patient populations, doses, and/or routes of administration, has been in existence for many years. Currently, there is a limited frequency and prevalence of research on the off-label use of antineoplastic drugs, mainly due to incomplete definition and classification issues. It is time to embrace new categories for the off-label usage of anticancer drugs.
View Article and Find Full Text PDFObjective: To develop a Risk Assessment Tool for Cancer-related Venous Thrombosis in China.
Methods: A modified two-round Delphi method was employed to establish consensus within a field to reach an agreement via a questionnaire or by interviewing a multidisciplinary panel of experts by collecting their feedback to inform the next round, exchanging their knowledge, experience, and opinions anonymously, and resolving uncertainties. Furthermore, The AHP (Analytic Hierarchy Process) was used to determine the final quality indicators' relative importance.
Purpose: To analyze the characteristics of overlapping meta-analyses based on randomized controlled trials (RCTs) which reported PD-1/PD-L1 inhibitors in non-small cell cancer (NSCLC).
Methods: Meta-analyses were identified from English and Chinese databases until January 1, 2022. Differences in characteristics of overlapping meta-analyses that conducted in China and other countries were compared to assess their publication propensity.
Article Synopsis
- - The study evaluated the effectiveness and safety of PD-1/PD-L1 inhibitors in treating oesophageal cancer (EC), gastric cancer (GC), and colorectal cancer (CRC), finding inconsistent results that complicated clinical decision-making.
- - A total of 23 trials were reviewed, highlighting varying ASCO-VF scores, with only 42.9% of regimens reaching ESMO-MCBS benefit thresholds; notably, pembrolizumab showed value in advanced microsatellite instability-high CRC, while PD-1/PD-L1 inhibitors were less effective for GC/GEJC.
- - The findings indicated a negative correlation between the cost and value of these treatments, suggesting that while some inhibitors may provide benefits, their cost-effectiveness varies
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
Front Public Health
March 2023
Background: Whether the high cost of cancer drugs is commensurate with their value to patients, which has become the focus of public concern. We aimed to assess the value of new cancer drugs approved for solid cancer in China and to explore the association between price and value of drugs.
Methods: We identified all new drugs for solid tumor that approved by the China's National Medical Products Administration (NMPA) between 2016 and 2020.
Background: An influx of systematic reviews (SRs) of programmed cell death 1 (PD-1) and programmed death ligand-1 (PD-L1) checkpoint inhibitors in cancer treatment with or without meta-analysis and with different methodological quality and inconsistent results have been published, confusing clinical decision making. The aim of this study was to comprehensively evaluate and summarize the current evidence of PD-(L)1 inhibitors in the treatment of cancer.
Methods: A comprehensive search of SRs, which included meta-analyses of PD-(L)1 inhibitors on cancer, was performed on eight databases with a cutoff date of 1 January 2022.
Objective: This study aims to compare the efficacy and safety of different poly (ADP-ribose) polymerase (PARP) inhibitors in patients with ovarian cancer through a network meta-analysis to support clinical treatment choices.
Methods: The Cochrane Library, PubMed, Embase, Science Citation Index, China National Knowledge Infrastructure (CNKI), Wanfang Data, Chongqing VIP (CQVIP), and Chinese BioMedical Literature Database (CBM) were searched with a cutoff date of 14 January 2021. ClinicalTrials.